Balovaptan did not improve socialization and communication difficulties in adults with autism spectrum disorder, according to results of a phase 3 randomized, placebo-controlled, double-blind clinical trial published in Lancet Psychiatry.
“Although the cause of autism spectrum disorder is not fully understood, several key brain signaling pathways have been implicated in its development,” Suma Jacob, MD, PhD, associate professor, department of psychiatry at the University of Minnesota, and colleagues wrote. “One such pathway is the vasopressin system. Preclinical evidence